InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.66
(
-0.15%
)
Bitcoin
64,940.78
(
-0.30%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: DewDiligence post# 156565

Thursday, 02/07/2013 6:29:59 AM

Thursday, February 07, 2013 6:29:59 AM

Post# of 252254

I don’t think GILD will include genotype-3 in the Sofusbuvir/ribavirin NDA submission if they can’t do better than the 56% SVR seen in FISSION.





If GILD pursues approval in both genotypes do you agree the FDA would request separate filings due to the large disparity in SVR rates?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up